The baseline characteristics of the 4133 patients in the I-PRESERVE trial are broadly representative of real-world patients with HFpEF.
Supports I-PRESERVE generalizability to real-world HFpEF; leaves open direct practice implications pending prospective validation.
Patients in I-PRESERVE are broadly representative of those seen in epidemiological studies and, because of this, the results of this trial should be generally applicable to "real world" patients with heart failure and preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
McMurray et al. (2008) studied this question.